Company intelligence / Profile preview

BenevolentAI

Ownership: Private
Employees: ~375
Development stage: Other

Overview

BEN‑2293 completed Phase IIa study for atopic dermatitis with top-line results anticipated March–April 2023. The ulcerative colitis program advanced a novel candidate to IND-enabling studies within two years from target validation. All pipeline assets are generated using the proprietary Benevolent Platform™.

Therapeutic areas: GastroenterologyPulmonologyDermatologyOncologyNeurology
Modalities: Small moleculesModality agnostic approaches (platform can address multiple modalities)
Industry: Biotech

Drug pipeline

3 assets

bavisant

2 more assets in the full pipeline.

Partnerships

Novartis – Framework collaboration agreement on oncology asset development using the Benevolent Platform® for patient stratification and trial optimization.AstraZeneca – Multi-year Target-ID collaboration expanded to systemic lupus erythematosus & heart failure as of January 2022.

Beyond the preview

Go deeper on BenevolentAI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BenevolentAI.